Trial · NCT01340937
Outcomes33
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 33
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | µg/mL | GEOMETRIC_MEAN |
| SECONDARY | Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Percentage of participants | NUMBER |
| PRIMARY | Geometric Mean Concentration of Antibodies to Hepatitis B Surface Antigen | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | mIU/mL | GEOMETRIC_MEAN |
| PRIMARY | Geometric Mean Concentration of Antibodies to Diphtheria Toxin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | IU/mL | GEOMETRIC_MEAN |
| PRIMARY | Geometric Mean Concentration of Antibodies to Tetanus Toxin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | IU/mL | GEOMETRIC_MEAN |
| PRIMARY | Geometric Mean Concentration of Antibodies to Pertussis Toxin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | EU/mL | GEOMETRIC_MEAN |
| PRIMARY | Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | EU/mL | GEOMETRIC_MEAN |
| PRIMARY | Geometric Mean Concentration of Antibodies to Pertussis Pertactin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | EU/mL | GEOMETRIC_MEAN |
| PRIMARY | Geometric Mean Concentration of Antibodies to Pertussis Fimbriae | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | EU/mL | GEOMETRIC_MEAN |
| PRIMARY | Geometric Mean Titer for Antibodies to Poliovirus Type 1 | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Titer | GEOMETRIC_MEAN |
| PRIMARY | Geometric Mean Titer for Antibodies to Poliovirus Type 2 | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Titer | GEOMETRIC_MEAN |
| PRIMARY | Geometric Mean Titer for Antibodies to Poliovirus Type 3 | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Titer | GEOMETRIC_MEAN |
| SECONDARY | Percentage of Participants Responding to Hepatitis B Surface Antigen | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Responding to Diphtheria Toxin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Responding to Tetanus Toxin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Responding to Pertussis Toxin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Responding to Pertussis Pertactin | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Responding to Pertussis Fimbriae | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Responding to Poliovirus Type 1 | Postdose 3 (Month 7) | The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3. | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01340937/outcomes